Canada markets open in 1 hour 33 minutes
  • S&P/TSX

    19,258.32
    +195.41 (+1.03%)
     
  • S&P 500

    3,900.11
    -11.63 (-0.30%)
     
  • DOW

    31,438.26
    -62.42 (-0.20%)
     
  • CAD/USD

    0.7786
    +0.0017 (+0.22%)
     
  • CRUDE OIL

    111.19
    +1.62 (+1.48%)
     
  • BTC-CAD

    26,998.69
    -551.82 (-2.00%)
     
  • CMC Crypto 200

    459.17
    -2.62 (-0.57%)
     
  • GOLD FUTURES

    1,825.10
    +0.30 (+0.02%)
     
  • RUSSELL 2000

    1,771.74
    +6.01 (+0.34%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,107.25
    +66.75 (+0.55%)
     
  • VOLATILITY

    26.95
    -0.28 (-1.03%)
     
  • FTSE

    7,352.32
    +94.00 (+1.30%)
     
  • NIKKEI 225

    27,049.47
    +178.20 (+0.66%)
     
  • CAD/EUR

    0.7367
    +0.0031 (+0.42%)
     

COVID shot drives CanSinoBIO's first six-month profit since at least 2019

·1 min read
FILE PHOTO: China's vaccine specialist CanSino Biologics Inc in Tianjin

BEIJING (Reuters) - Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of its COVID-19 shot. That compared with 123.0 million yuan of operating loss in the same period a year ago, CanSinoBIO said in a filing in the Hong Kong stock exchange. It marks the first six-month profit since at least 2019. The firm is yet to achieve full-year profits since it went public in 2018 in Hong Kong.

It reported 937.1 million yuan profit and total comprehensive income for the first six months of 2021. Its single-dose COVID-19 shot, named Ad5-nCoV, has been approved for use in countries including China, Mexico, Pakistan and Chile. The vaccine approvals were one of the major drivers for the sixth-month profit, CanSinoBIO said.

($1 = 6.4813 Chinese yuan renminbi)

(Reporting by Roxanne Liu and Ryan Woo; Editing by Catherine Evans)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting